JPH10500988A - 輸送タンパク質用クロストリジウム属細菌毒素の修飾 - Google Patents
輸送タンパク質用クロストリジウム属細菌毒素の修飾Info
- Publication number
- JPH10500988A JPH10500988A JP8500524A JP50052496A JPH10500988A JP H10500988 A JPH10500988 A JP H10500988A JP 8500524 A JP8500524 A JP 8500524A JP 50052496 A JP50052496 A JP 50052496A JP H10500988 A JPH10500988 A JP H10500988A
- Authority
- JP
- Japan
- Prior art keywords
- chain
- botulinum toxin
- toxin
- bont
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.神経細胞に関連する障害を治療するための化学物質結合体であって、標的神 経細胞に対して特異性を有する不活性なクロストリジウム属細菌神経毒素と前記 神経毒素に結合した医薬または他の生物活性分子とを含み、前記神経毒素が前記 標的神経細胞に侵入する能力を維持している化学物質結合体。 2.前記クロストリジウム属細菌神経毒素がテタヌストキシン、ボツリヌス毒素 A、ボツリヌス毒素B、ボツリヌス毒素C、ボツリヌス毒素D、ボツリヌス毒素 E、ボツリヌス毒素Fおよびボツリヌス毒素Gからなる群より選ばれる請求項1 に記載の化学物質結合体。 3.前記クロストリジウム属細菌神経毒素が、その軽鎖中のアミノ酸の変更によ り不活性化されている請求項1に記載の化学物質結合体。 4.前記不活性化されたクロストリジウム属細菌神経毒素が、Glu234の修飾 を有するテタヌストキシン、His227および/またはGlu224に修飾を有する ボツリヌス毒素A、またはボツリヌス毒素AのHis227および/またはGlu2 24 に対応する部位に修飾を有するボツリヌス毒素A以外のボツリヌス毒素である 請求項3に記載の化学物質結合体。 5.哺乳類の神経筋機能障害の治療に用いられる請求項1〜4のいずれかに記載 の化学物質結合体。 6.制御不能な筋痙攣に関連する神経筋障害の治療に用いられる請求項5に記載 の化学物質結合体。 7.哺乳類での神経筋機能障害の治療用の薬剤の調製における請求項1〜4のい ずれかに記載の化学物質結合体の使用。 8.前記神経筋機能障害が、制御不能な筋痙攣に関連する請求項7に記載の使用 。 9.前記医薬が、ボツリヌス中毒または破傷風の治療用の有効成分である請求項 1〜4のいずれかに記載の化学物質結合体。 10.ボツリヌス中毒または破傷風の治療に用いられる請求項9の化学物質結合 体。 11.哺乳類でのボツリヌス中毒または破傷風の治療用の薬剤の調製における請 求項9に記載の化学物質結合体の使用。 12.急性のボツリヌス毒素中毒の治療用の薬剤の調製における不活性クロスト リジウム属細菌神経毒素の使用。 13.前記クロストリジウム属細菌神経毒素が、他の医薬と複合せずに用いられ る請求項12に記載の使用。 14.限局性ジストニー、ストローク若しくは外傷性脳損傷若しくは脊椎の損傷 による痙直、眼瞼痙攣、斜視、脳性小児麻痺または筋痙攣による背痛の治療用薬 剤の調製における、活性クロストリジウム属細菌神経毒素と医薬とを含む化学物 質結合体の使用。 15.哺乳類の神経筋機能障害の治療方法であって、医薬が結合されたクロスト リジウム属細菌神経毒素を含む医薬的に活性のある溶液を調製し、有効量の前記 薬学的に活性のある溶液を哺乳類に導入することを特徴とする方法。 16.前記クロストリジウム属細菌神経毒素が、テタヌストキシン、ボツリヌス 毒素A、ボツリヌス毒素B、ボツリヌス毒素C、ボツリヌス毒素D、ボツリヌス 毒素E、ボツリヌス毒素Fおよびボツリヌス毒素Gからなる群より選ばれる請求 項15に記載の方法。 17.前記クロストリジウム属細菌神経毒素が、その軽鎖中のアミノ酸の変更に より不活性化されている請求項15に記載の方法。 18.前記医薬が、神経伝達物質の放出を抑制する請求項15に記載の方法。 19.前記医薬が、シナプトブレビン(synaptobrevin)の活性を抑制する請求 項18に記載の方法。 20.前記神経筋機能障害が、制御不能な筋痙攣に関連する請求項15に記載の 方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9410870A GB9410870D0 (en) | 1994-05-31 | 1994-05-31 | Modification of botulinum toxins for use as transport proteins |
GB9410871A GB9410871D0 (en) | 1994-05-31 | 1994-05-31 | Modification of tetanus toxin for use as a transport protein |
GB9410870.1 | 1994-05-31 | ||
GB9410871.9 | 1994-05-31 | ||
PCT/GB1995/001253 WO1995032738A1 (en) | 1994-05-31 | 1995-05-31 | Modification of clostridial toxins for use as transport proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10500988A true JPH10500988A (ja) | 1998-01-27 |
JP3523879B2 JP3523879B2 (ja) | 2004-04-26 |
Family
ID=26304971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50052496A Expired - Fee Related JP3523879B2 (ja) | 1994-05-31 | 1995-05-31 | 輸送タンパク質用クロストリジウム属細菌毒素の修飾 |
Country Status (9)
Country | Link |
---|---|
US (1) | US6203794B1 (ja) |
EP (1) | EP0760681B1 (ja) |
JP (1) | JP3523879B2 (ja) |
AU (1) | AU695623B2 (ja) |
CA (1) | CA2191754C (ja) |
DE (1) | DE69511860T2 (ja) |
DK (1) | DK0760681T3 (ja) |
ES (1) | ES2138740T3 (ja) |
WO (1) | WO1995032738A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002532560A (ja) * | 1998-12-21 | 2002-10-02 | ザヴォス | 治療成分を神経細胞に細胞内送達するための化合物 |
WO2005009475A1 (ja) * | 2003-07-25 | 2005-02-03 | Yukako Fujinaga | クロストリジウム属菌由来成分を含む医薬製剤 |
JP2005506277A (ja) * | 2000-12-29 | 2005-03-03 | アラーガン、インコーポレイテッド | 疼痛治療のための薬剤および方法 |
JP2010222367A (ja) * | 2002-06-26 | 2010-10-07 | Allergan Inc | 持続勃起症を処置するためのボツリヌス毒素 |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7227010B2 (en) | 1993-09-21 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Army | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
US7214787B1 (en) * | 1993-09-21 | 2007-05-08 | United States Of America As Represented By The Secretary Of The Army | Recombinant vaccine against botulinum neurotoxin |
US6967088B1 (en) * | 1995-03-16 | 2005-11-22 | Allergan, Inc. | Soluble recombinant botulinum toxin proteins |
GB9524807D0 (en) * | 1995-12-05 | 1996-02-07 | Smithkline Beecham Plc | Novel compounds |
WO1997034620A1 (en) * | 1996-03-18 | 1997-09-25 | The Regents Of The University Of California | Peptide inhibitors of neurotransmitter secretion by neuronal cells |
US6444209B1 (en) | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
US5939070A (en) * | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
GB9721189D0 (en) * | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
US6051239A (en) * | 1997-10-20 | 2000-04-18 | Thomas Jefferson University | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
EP1053014A4 (en) | 1998-01-26 | 2004-11-10 | Univ Massachusetts | BIOLOGICALLY ACTIVE HEMAGGLUTININE TYPE A i (STRIDIUM BOTULINUM) AND METHOD FOR ITS USE |
DE19856052A1 (de) * | 1998-12-04 | 2000-06-08 | Deutsches Krebsforsch | Konjugat zur Anreicherung in neuronalen Zellen |
US20040120891A1 (en) | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
GB9907429D0 (en) | 1999-03-31 | 1999-05-26 | Microbiological Res Authority | Modulation of C-fibre activity |
US6776990B2 (en) * | 1999-04-08 | 2004-08-17 | Allergan, Inc. | Methods and compositions for the treatment of pancreatitis |
WO2001018038A2 (en) * | 1999-08-20 | 2001-03-15 | Imperial College Innovations Limited | Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis |
EP2267010B1 (en) | 1999-08-25 | 2014-05-07 | Allergan, Inc. | Activatable recombinant neurotoxins |
US7740868B2 (en) | 1999-08-25 | 2010-06-22 | Allergan, Inc. | Activatable clostridial toxins |
US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
US6500436B2 (en) | 2000-01-19 | 2002-12-31 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US7138127B1 (en) | 2000-01-19 | 2006-11-21 | Allergan, Inc. | Clostridial toxin derivatives and methods for treating pain |
US6670322B2 (en) * | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
US6423319B1 (en) | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
AU2002228887B2 (en) * | 2000-11-06 | 2006-08-24 | United States Army Medical Research And Material Command | Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy |
US7273722B2 (en) * | 2000-11-29 | 2007-09-25 | Allergan, Inc. | Neurotoxins with enhanced target specificity |
EP1386968A4 (en) * | 2001-04-09 | 2004-12-22 | Mitsubishi Pharma Corp | UNIT TO CONTROL AND USE GENE EXPRESSION |
JP4707254B2 (ja) * | 2001-04-24 | 2011-06-22 | クミアイ化学工業株式会社 | 粒状組成物及びその製造方法 |
GB0112687D0 (en) * | 2001-05-24 | 2001-07-18 | Microbiological Res Authority | Pharmaceutical use of secreted bacterial effector proteins |
JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
US6921538B2 (en) | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
NZ537120A (en) * | 2002-05-31 | 2008-07-31 | Univ Jefferson | Compositions and methods for transepithelial molecular transport |
AU2003272800A1 (en) * | 2002-10-01 | 2004-04-23 | University Of Maryland | Methods for identifying inhibitors of botulinum neurotoxins |
US20040115727A1 (en) * | 2002-12-11 | 2004-06-17 | Allergan, Inc., A Corporation | Evolved clostridial toxins with altered protease specificity |
KR20050094817A (ko) * | 2002-12-20 | 2005-09-28 | 보툴리늄 톡신 리서치 어쏘시에이츠, 인크. | 개선된 약제학적 보툴리늄 독소 조성물 |
US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
US7514088B2 (en) | 2005-03-15 | 2009-04-07 | Allergan, Inc. | Multivalent Clostridial toxin derivatives and methods of their use |
US7811584B2 (en) * | 2004-06-30 | 2010-10-12 | Allergan, Inc. | Multivalent clostridial toxins |
US7785606B2 (en) * | 2004-11-22 | 2010-08-31 | New York University | Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof |
DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
CA2610103A1 (en) * | 2005-09-19 | 2007-03-19 | Allergan, Inc. | Clostridial toxin activatable clostridial toxins |
EP2505592A1 (en) | 2006-07-11 | 2012-10-03 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity |
AU2007272515B2 (en) | 2006-07-11 | 2013-09-26 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
WO2009038770A2 (en) * | 2007-09-20 | 2009-03-26 | University Of Massachusetts Cvip | Detoxified recombinant botulinum neurotoxin |
WO2009131435A1 (en) * | 2008-04-23 | 2009-10-29 | Erasmus University Medical Center Rotterdam | Linker containing bungarotoxin and a binding peptide |
EP2364168A1 (en) | 2008-12-04 | 2011-09-14 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
US8492109B2 (en) * | 2009-01-20 | 2013-07-23 | Trustees Of Tufts College | Methods for the delivery of toxins or enzymatically active portions thereof |
EP2218783A1 (en) | 2009-02-05 | 2010-08-18 | Merz Pharma GmbH & Co. KGaA | Novel method for the manufacturing of neurotoxins |
US20120244188A1 (en) * | 2011-03-25 | 2012-09-27 | Allergan, Inc. | Treatment of Sensory Disturbance Disorders |
US20140377248A1 (en) | 2011-12-23 | 2014-12-25 | Merz Pharma Gmbh & Co. Kgaa | Method for the manufacturing of di-chain proteins for use in humans |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
JP6336970B2 (ja) | 2012-05-30 | 2018-06-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | 操作されたボツリヌス神経毒素 |
US9005628B2 (en) | 2012-10-04 | 2015-04-14 | Dublin City University | Biotherapy for pain |
WO2014117148A1 (en) | 2013-01-28 | 2014-07-31 | New York University | Treatment methods using atoxic neurotoxin derivatives |
US9216210B2 (en) | 2013-12-23 | 2015-12-22 | Dublin City University | Multiprotease therapeutics for chronic pain |
US9975929B2 (en) | 2014-03-05 | 2018-05-22 | Merz Pharma Gmbh & Co. Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
WO2016094555A1 (en) | 2014-12-09 | 2016-06-16 | New York University | Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use |
ES2837699T3 (es) | 2014-12-19 | 2021-07-01 | Merz Pharma Gmbh & Co Kgaa | Medios y métodos para la determinación de la actividad biológica de BoNT/E en células |
DK3274364T3 (da) | 2015-03-26 | 2021-10-18 | Harvard College | Modificeret botulinumneurotoksin |
TW201718627A (zh) | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
US11078472B2 (en) | 2016-01-20 | 2021-08-03 | Merz Pharma Gmbh & Co., Kgaa | Recombinant clostridial neurotoxins with increased duration of effect |
CA3010146A1 (en) | 2016-03-02 | 2017-09-08 | Merz Pharma Gmbh & Co. Kgaa | Composition comprising botulinum toxin |
EP3504226A1 (en) | 2016-08-24 | 2019-07-03 | President and Fellows of Harvard College | Engineered botulinum neurotoxin |
EP3290437A1 (en) | 2016-08-31 | 2018-03-07 | Merz Pharma GmbH & Co. KGaA | Novel recombinant clostridial neurotoxins with decreased duration of effect |
AU2017326253B2 (en) | 2016-09-13 | 2021-10-21 | Allergan, Inc. | Stabilized non-protein clostridial toxin compositions |
EP3312193A1 (en) | 2016-10-19 | 2018-04-25 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with accelerated onset of effect |
DK3529616T3 (da) | 2016-10-20 | 2023-12-11 | Harvard College | In vitro- og cellebaserede assays til måling af aktiviteten af botulinum-neurotoksiner |
EP3333179A1 (en) | 2016-12-07 | 2018-06-13 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum toxin with accelarated onset of effect |
EP3335719A1 (en) | 2016-12-14 | 2018-06-20 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with a stabilized light chain |
US11952601B2 (en) | 2017-06-20 | 2024-04-09 | Merz Pharma Gmbh & Co. Kgaa | Recombinant botulinum toxin with increased duration of effect |
EP3649143B1 (en) | 2017-07-06 | 2022-08-31 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
EP3700919A1 (en) | 2017-10-26 | 2020-09-02 | Merz Pharma GmbH & Co. KGaA | Novel recombinant botulinum neurotoxins with increased duration of effect |
US20200354706A1 (en) | 2017-11-22 | 2020-11-12 | Merz Pharma Gmbh & Co. Kgaa | Novel recombinant botulinum toxin with increased duration of effect |
EP3823674A4 (en) | 2018-07-18 | 2022-12-28 | Manzanita Pharmaceuticals, Inc. | CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF |
WO2023105289A1 (en) | 2021-12-06 | 2023-06-15 | Dublin City University | Methods and compositions for the treatment of pain |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4594336A (en) * | 1982-09-28 | 1986-06-10 | Institut Pasteur | Thiolated polypeptide compound derived from a tetanus toxin fragment, the process for obtaining and its application |
US4713240A (en) * | 1985-04-04 | 1987-12-15 | Research Corporation | Vaccines based on insoluble supports |
US5204097A (en) * | 1986-07-06 | 1993-04-20 | Yeda Research And Development Company Limited | Shiga toxin B chain polypeptides and vaccine thereto |
IL79346A0 (en) * | 1986-07-06 | 1986-10-31 | Yeda Res & Dev | Shiga vaccine |
US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
US5196193A (en) * | 1989-10-31 | 1993-03-23 | Ophidian Pharmaceuticals, Inc. | Antivenoms and methods for making antivenoms |
US5719267A (en) * | 1989-10-31 | 1998-02-17 | Ophidian Pharmaceuticals Inc. | Clostridial toxin disease therapy |
US5736139A (en) * | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
US5599539A (en) * | 1989-10-31 | 1997-02-04 | Ophidian Pharmaceuticals, Inc. | Therapy for clostridial botulinum toxin |
US5601823A (en) * | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
CA2129899C (en) * | 1992-02-11 | 2011-01-04 | James J. Mond | Dual carrier immunogenic construct |
WO1994000481A1 (en) * | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Pharmaceutical composition containing botulinum b complex |
WO1994000487A1 (en) * | 1992-06-30 | 1994-01-06 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Peptide which produces protective immunity against tetanus |
GB9305735D0 (en) | 1993-03-19 | 1993-05-05 | North John R | Novel agent for controlling cell activity |
US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
US5693476A (en) * | 1995-02-24 | 1997-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of screening for compounds capable of modulating vesicular release |
US5650280A (en) * | 1995-03-23 | 1997-07-22 | Incyte Pharmaceuticals, Inc. | Cellubrevin homolog |
US5721215A (en) * | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
US5965699A (en) * | 1996-11-06 | 1999-10-12 | The United States Of America As Represented By The Secretary Of The Army | Assay for the proteolytic activity of serotype a from clostridium botulinum |
US5955368A (en) * | 1998-04-06 | 1999-09-21 | Wisconsin Alumni Research Foundation | Expression system for clostridium species |
-
1995
- 1995-05-31 EP EP95921007A patent/EP0760681B1/en not_active Expired - Lifetime
- 1995-05-31 DK DK95921007T patent/DK0760681T3/da active
- 1995-05-31 AU AU26222/95A patent/AU695623B2/en not_active Ceased
- 1995-05-31 JP JP50052496A patent/JP3523879B2/ja not_active Expired - Fee Related
- 1995-05-31 CA CA002191754A patent/CA2191754C/en not_active Expired - Fee Related
- 1995-05-31 US US08/750,101 patent/US6203794B1/en not_active Expired - Fee Related
- 1995-05-31 ES ES95921007T patent/ES2138740T3/es not_active Expired - Lifetime
- 1995-05-31 WO PCT/GB1995/001253 patent/WO1995032738A1/en active IP Right Grant
- 1995-05-31 DE DE69511860T patent/DE69511860T2/de not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002532560A (ja) * | 1998-12-21 | 2002-10-02 | ザヴォス | 治療成分を神経細胞に細胞内送達するための化合物 |
JP2005506277A (ja) * | 2000-12-29 | 2005-03-03 | アラーガン、インコーポレイテッド | 疼痛治療のための薬剤および方法 |
JP2010222367A (ja) * | 2002-06-26 | 2010-10-07 | Allergan Inc | 持続勃起症を処置するためのボツリヌス毒素 |
JP2013166792A (ja) * | 2002-06-26 | 2013-08-29 | Allergan Inc | 持続勃起症を処置するためのボツリヌス毒素 |
WO2005009475A1 (ja) * | 2003-07-25 | 2005-02-03 | Yukako Fujinaga | クロストリジウム属菌由来成分を含む医薬製剤 |
Also Published As
Publication number | Publication date |
---|---|
EP0760681A1 (en) | 1997-03-12 |
DE69511860T2 (de) | 2000-02-10 |
CA2191754C (en) | 2000-12-12 |
DK0760681T3 (da) | 2000-03-27 |
CA2191754A1 (en) | 1995-12-07 |
EP0760681B1 (en) | 1999-09-01 |
ES2138740T3 (es) | 2000-01-16 |
AU695623B2 (en) | 1998-08-20 |
JP3523879B2 (ja) | 2004-04-26 |
AU2622295A (en) | 1995-12-21 |
DE69511860D1 (de) | 1999-10-07 |
US6203794B1 (en) | 2001-03-20 |
WO1995032738A1 (en) | 1995-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10500988A (ja) | 輸送タンパク質用クロストリジウム属細菌毒素の修飾 | |
AU2002229075B2 (en) | Agents and methods for treating pain | |
US7456272B2 (en) | Neurotoxins with enhanced target specificity | |
US7723480B2 (en) | Leucine-based motif and clostridial neurotoxins | |
DE60032367T2 (de) | Aktivierbare rekombinante neurotoxine | |
RU2748653C2 (ru) | Жидкая композиция, содержащая ботулотоксин и стабилизирующий агент, и способ её получения | |
AU2002229075A1 (en) | Agents and methods for treating pain | |
CN102131823A (zh) | 具有改变的持久性的梭状芽孢杆菌神经毒素 | |
JP6378772B2 (ja) | 慢性疼痛のためのマルチプロテアーゼ(multiprotease)治療薬 | |
KR20080106451A (ko) | 페그화된 돌연변이 클로스트리디움 보툴리눔 독소 | |
Li et al. | Expression and characterisation of the heavy chain of tetanus toxin: reconstitution of the fully-recombinant dichain protein in active form | |
US7628992B1 (en) | Modification of clostridial toxins for use as transport proteins | |
US20070048335A1 (en) | Methods for treating pain and hyperhidrosis | |
AU2002228684A1 (en) | Neurotoxins with enhanced target specificity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20040115 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040127 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040210 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080220 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080220 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090220 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090220 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100220 Year of fee payment: 6 |
|
LAPS | Cancellation because of no payment of annual fees |